<DOC>
	<DOCNO>NCT03060538</DOCNO>
	<brief_summary>This Phase Ib , randomize , blind , placebo-controlled , multiple ascending−dose study safety , tolerability , pharmacokinetic ( PK ) , pharmacodynamic ( PD ) effect BFKB8488A participant Type 2 diabetes mellitus . A maximum approximately 140 participant enrol across multiple site United States . Participants randomly assign receive study drug ( active BFKB8488A placebo ) . The study consist screen period ( 6 week ) , 12-week treatment period , 6-week follow-up period .</brief_summary>
	<brief_title>A Phase Ib Multiple Ascending Dose Study Evaluate Safety Tolerability BFKB8488A Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Body mass index ( BMI ) ≥ 27 kg/m2 ≤ 40 kg/m2 A confirm diagnosis Type 2 diabetes ≥ 6 month screen Current stable treatment ( least 3 month ) diabetes Hemoglobin A1c ( HbA1c ) ≥ 6.8 % ≤ 9.0 % For woman childbearing potential , agreement remain abstinent use reliable contraception treatment period least 42 day last dose study drug For men , agreement remain abstinent use reliable contraception agree refrain donate sperm Pregnant , lactating , intend become pregnant within 3 month last dose study drug administer Suspected confirm diagnosis Type 1 diabetes Significant cardiac disease Any psychiatric illness increase risk participation study History severe allergic , anaphylactic , hypersensitivity reaction , severe systemic bacterial , fungal , parasitic infection Poor peripheral venous access Received blood product within 2 month dose Donation loss blood within 3056 day prior study drug administration Positive hepatitis C virus ( HCV ) antibody , hepatitis B surface antigen ( HBsAg ) , human immunodeficiency virus ( HIV ) antibody Liver enzymes great acceptable limit History eat disorder surgical procedure weight loss Active participation structure weight loss dietary program Treatment investigational therapy exposure biological therapy Illicit drug use , marijuana use , alcohol abuse Current use one pack cigarettes day equivalent nicotinecontaining product Any serious medical condition abnormality clinical laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>